Table 4. Association of serum miRNA ratios with risk of NMIBC.

	Discovery				Validation				Combined
miRNA ratio	Cases N (%)	Controls N (%)	OR* (95% CI)	P-value	Cases N (%)	Controls N (%)	OR* (95% CI)	P-value	Cases N (%)	Controls (%)	OR* (95% CI)	P-value
409-3p/423-5p
Low	79 (58.96)	55 (41.04)	1 (reference)		78 (54.93)	64 (45.07)	1 (reference)		157 (56.88)	119 (43.12)	1 (reference)
High	41 (42.27)	56 (57.73)	0.48 (0.27–0.84)	0.01	44 (41.51)	62 (58.49)	0.54 (0.31–0.94)	0.03	85 (41.87)	118 (58.13)	0.50 (0.34–0.74)	<0.001
29c-3p/331-3p
Low	40 (42.11)	55 (57.89)	1 (reference)		36 (38.30)	58 (61.70)	1 (reference)		76 (40.21)	113 (59.79)	1 (reference)
High	67 (54.92)	55 (45.08)	1.80 (1.00–3.22)	0.048	76 (57.14)	57 (42.86)	2.34 (1.31–4.16)	0.004	143 (56.08)	112 (43.92)	2.02 (1.34–3.03)	<0.001
331-3p/423-5p
Low	70 (59.32)	48 (40.68)	1 (reference)		77 (53.47)	67 (46.53)	1 (reference)		147 (56.11)	115 (43.89)	1 (reference)
High	43 (42.57)	58 (57.43)	0.43 (0.24–0.77)	0.004	41 (41.84)	57 (58.16)	0.55 (0.31–0.97)	0.039	84 (42.21)	115 (57.79)	0.51 (0.34–0.75)	<0.001
29a-3p/222-3p
Low	43 (40.95)	62 (59.05)	1 (reference)		43 (41.75)	60 (58.25)	1 (reference)		86 (41.35)	122 (58.65)	1 (reference)
High	78 (59.09)	54 (40.91)	1.97 (1.13–3.42)	0.016	84 (55.63)	67 (44.37)	1.85 (1.09–3.14)	0.023	162 (57.24)	121 (42.76)	1.90 (1.30–2.78)	0.001
146a-5p/423-5p
Low	71 (57.26)	53 (42.74)	1 (reference)		79 (54.48)	66 (45.52)	1 (reference)		150 (55.76)	119 (44.24)	1 (reference)
High	47 (43.93)	60 (56.07)	0.53 (0.30–0.92)	0.025	47 (44.34)	59 (55.66)	0.54 (0.31–0.94)	0.029	94 (44.13)	119 (55.87)	0.54 (0.37–0.79)	0.002
150-5p/331-3p
Low	36 (40.00)	54 (60.00)	1 (reference)		48 (40.68)	70 (59.32)	1 (reference)		84 (40.38)	124 (59.62)	1 (reference)
High	82 (57.75)	60 (42.25)	1.94 (1.10–3.42)	0.022	72 (53.33)	63 (46.67)	1.72 (1.01–2.92)	0.044	154 (55.60)	123 (44.40)	1.82 (1.24–2.66)	0.002

^*Adjusted by age, sex and smoking status.